Meet us in Dublin for #BIOEquity 2023! From May 14-16 our CEO, Dr. Richard Jones, and CFO, David Germonpré, will be on-site and present at the Convention Centre Dublin to share insights on how we want to help critically ill #patients suffering from #septic shock.

Adrenomed is @Bio€quity! Our CEO, Dr. Richard Jones, and CFO, David Germonpré, are on-site for presenting, partnering and pitches. Get in touch for insights on how we help critically ill #patients suffering from #sepsis.

Thank you #BioEquity! We enjoyed 2 days of excellent meetings in Dublin, and we were excited to present our plans for late-stage drug candidate #Adrecizumab to treat #septicshock. We are looking forward to BioEquity digital next week on May 22-23! #biotech #sepsis

Thank you #3CT for 3 days of ground-breaking discussions on trial design, conduct & data interpretation in critical care. Prof Laterre presented the future clinical development of enibarcimab in septic shock, and our CMO Stephan Witte took the stage on endpoints in sepsis trials

We’re excited to be at the Great Network Meeting with some of the world’s leading #criticalcare experts this year in Berlin. Don’t miss the presentations highlighting safety and mechanism of action data from an enibarcimab pilot study in patients with acute heart failure. #AHF

Our CEO, Richard Jones, takes this years’ #Sepsisawarenessmonth, September, to set the limelight onto this critical condition and to emphasize the need for more attention with all stakeholders. Learn more on sepsis here: bit.ly/44A5aXJ

Adrenomed’s CEO Richard Jones and CMO Dr. Stephan Witte spoke to International Clinical Trials (ICT online) about the status quo, prevention and treatment approaches for #sepsis and #septicshock. See more: bit.ly/44A5aXJ

Two highlights coming up on Friday: At 09:30, don’t miss Matthijs Kox's presenting new data on our Adrenomed compound enibarcimab. Then, delve deeper with poster presentation 48 in Session 2 at noon. Looking forward to insightful discussions and exchanges! #SepsisUpdate2023

Today at the 11th Weimar Sepsis Update, Prof. Matthijs Kox presented new findings that validate our biomarker-guided precision medicine strategy in the treatment of septic shock with enibarcimab. Learn more in our PR: bit.ly/3ZbaMXs

The Adrenomed team really enjoyed the high-profile scientific discussions at the Weimar #sepsisupdate2023. Thank you for the inspiring talk and poster presentation Prof. Kox and Prof. Pickkers!

Looking forward to insightful talks and discussions at today’s World Sepsis Day event! Catch our Head of R&D Joachim Struck on “Precision Medicine in New Therapies for Septic Shock”. Watch live at: worldsepsisday.org/programwsd2023 #WorldSepsisDay #PrecisionMedicine

sepsis-stiftung.de/blog/world-sep…

Every 3 to 4 seconds, someone is diagnosed with sepsis. Each year, 11 million people die from this complex condition. Please remember: Common infections can lead to sepsis. Let's raise awareness with SepsisAlliance. Learn more: sepsis.org #WorldSepsisDay #sepsis

Our CFO, David Germonpré is representing Adrenomed at the 23rd Annual Biotech in Europe Forum! Want to connect? Schedule a meeting with us to learn more about our phase 2b/3 study in septic shock. #biotech #pharma #networking #Adrenomed

As #SepsisAwarenessMonth concludes, we take a moment to reflect on the steps we've already taken and the challenges that remain. #sepsis #septicshock

Driving R&D to fight #sepsis is a round-the-clock task: In November we participated in #BIO-Europe, LSX and #Jefferies to raise sepsis awareness and bolster the development of our late-stage compound #enibarcimab.

We're excited to be in San Francisco from January 8-10 for J.P. Morgan week! Meet Dr. Richard Jones, CEO, and David Germonpré, CFO, to learn more about our late-stage drug candidate, Enibarcimab and how you can get involved. #Enibarcimab #SepticShock #JPM2024 #BiotechShowcase

Our CEO Richard Jones shared his outlook and challenges for 2024 in the Scrip Asks … series. In his words: “We owe success to millions of sepsis patients, past, present and future. Never surrender is our mission for 2024.” Read the full article here: bit.ly/3HgS6NG

The 43rd ISICEM wraps up after 4 amazing days! Thanks to all, especially Prof. Peter Pickkers for his Enibarcimab insights. Proud to be in this #scientificcommunity. See you next year! #ISICEM #septicshock #sepsis

This recently published review in Critical Care addresses “The challenge: What is the place for biomarkers in sepsis?” and discusses our Enibarcimab as example for a novel biomarker-guided treatment for #sepsis and #septicshock: doi.org/10.1186/s13054…